Bayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Japan

[at noodls] – TARRYTOWN, N.Y., March 3, 2014 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare’s Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application … moreView todays social media effects on REGNView the latest stocks trending across Twitter. Click to view dashboardSee who Regeneron is hiring next, click here to view […]